|
|
Home
Search
Study Topics
Glossary
|
 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|||||||||||||||||||||||||||||||||||||||||||||
| Sponsors and Collaborators: |
St. Michael's Hospital, Toronto Cystic Fibrosis Foundation Pfizer |
|---|---|
| Information provided by: | St. Michael's Hospital, Toronto |
| ClinicalTrials.gov Identifier: | NCT00298922 |
Purpose
Pulmonary infection with Burkholderia cepacia complex (BCC) in patients with CF is often associated with a more rapid decline in lung function. Because of the resistance of BCC to many antibiotics, treatment options are often limited. New therapies to improve outcomes for patients infected with BCC are needed.
However, because of the unpredictable nature of this pulmonary infection in CF, patients with BCC infection have been excluded from many CF therapeutic trials.
Recent published trials in the United States, Australia, and the United Kingdom have all demonstrated clinical benefits from prolonged administration of azithromycin in CF. In these trials, the vast majority of patients were chronically infected with Pseudomonas aeruginosa.
Patients with BCC were excluded from the US and UK trials, and only four patients with BCC infection were enrolled in the Australian trial. Thus, the effectiveness of azithromycin in CF patients infected with BCC is largely unknown and deserves further study.
The two main ways by which azithromycin is thought to help with the chronic lung infections seen in CF are by [a] reducing inflammation and [b] direct effects on the bacteria, in particular P. aeruginosa. BCC pulmonary infection in CF is often associated with a large inflammatory response similar to or more severe than P. aeruginosa infection. If azithromycin works mainly by an anti-inflammatory mechanism, it should also be helpful in CF patients infected with BCC.
Alternatively, azithromycin could have a direct effect on BCC as seen with P. aeruginosa as the two bacteria have many similarities.
| Condition | Intervention | Phase |
|---|---|---|
|
Cystic Fibrosis |
Drug: Azithromycin Drug: Placebo |
Phase II |
| Study Type: | Interventional |
| Study Design: | Treatment, Randomized, Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Placebo Control, Parallel Assignment, Safety/Efficacy Study |
| Official Title: | Phase II, Randomized, Double Blind, Placebo-Controlled Trial of Azithromycin in Patients With CF, Chronically Infected With Burkhoderia Cepacia Complex |
| Estimated Enrollment: | 45 |
| Study Start Date: | February 2006 |
| Estimated Study Completion Date: | October 2009 |
Show Detailed Description Eligibility| Ages Eligible for Study: | 19 Years and older |
| Genders Eligible for Study: | Both |
| Accepts Healthy Volunteers: | No |
Inclusion Criteria:
A. Informed consent and verbal assent as appropriate has been provided by the subject B. Ability to comply with medication use, study visits and study procedures as judged by the site Investigator C. Diagnosis of CF as defined by two or more clinical features of CF and a documented sweat chloride > 60 mEq/L by quantitative pilocarpine iontophoresis test or a genotype showing two well characterized disease causing mutations D. > 18 years of age E. Body weight > 40 kg F. BCC present in a sputum/throat culture > 1 year prior to screening and at screening G. FEV1 % predicted > 30% as calculated by the Knudsen reference equations H. Room air oximetry > 88% at rest I. Post-menarche females must be surgically sterile or using an effective form of contraception J. Predicted to live > 1 year and clinically stable at that time of enrollment as judged by the investigator.
Exclusion Criteria
A. History of chronic macrolide use, defined as regular macrolide antibiotic use within a three month period prior to enrollment in the study.
B. AST or ALT > 2.5 times the upper limit of normal performed at the local laboratories on two occasions prior to randomization.
C. Investigational drug use within 30 days of screening D. History of alcohol, illicit drug or medication abuse within 1 year of screening E. Use of intravenous antibiotics or oral antibiotics within 14 days of screening.
F. Use of low dose oral antibiotics (e.g. macrolides, tetracycline, sulfa) for acne or other conditions within 30 days of screening G. Use of systemic corticosteroids (> 20 mg of prednisone per day) within 30 days of screening H. Initiation of TOBI®, high dose ibuprofen, or rhDNase within 60 days of screening I. History of lung transplantation or currently on lung transplant list J. History of allergy to a macrolide antibiotic K. AFB smear positive at screening suggesting current NTM infection. L. Positive serum pregnancy test at screening (to be performed on all post-menarche females) M. Absolute neutrophil count < 1000 performed at the local laboratories on two occasions prior to randomization N. Creatinine > 1.5 times normal performed at the local laboratories on two occasions prior to randomization.
O. Chest x-ray changes or physical findings at screening that would compromise the safety of the patient or the quality of the study data P. Other major organ dysfunction
Exclusion Criteria:
-
Contacts and Locations| Contact: Myra E Slutsky, Hon. BA | 416-864-6060 ext 2887 | slutskym@smh.toronto.on.ca |
| Canada, Ontario | |
| St. Michael's Hospital | Recruiting |
| Toronto, Ontario, Canada, M5B1W8 | |
| Principal Investigator: Tullis Elizabeth, MD | |
| Principal Investigator: | Elizabeth Tullis, MD | University of Toronto |
More Information
| Responsible Party: | St. Michael's Hospital ( Dr. Elizabeth Tullis ) |
| Study ID Numbers: | AZ 0003, TULLIS04A0 |
| Study First Received: | March 2, 2006 |
| Last Updated: | July 16, 2008 |
| ClinicalTrials.gov Identifier: | NCT00298922 |
| Health Authority: | Canada: Health Canada |
|
Cystic Fibrosis Burkholderia cepacia complex |
|
Digestive System Diseases Genetic Diseases, Inborn Respiratory Tract Diseases Cystic Fibrosis Fibrosis |
Azithromycin Lung Diseases Infant, Newborn, Diseases Pancreatic Diseases Cystic fibrosis |
|
Anti-Infective Agents Anti-Bacterial Agents Pathologic Processes Therapeutic Uses Pharmacologic Actions |
